In this webinar, Dr. Roddy O’Connor will discuss how T cells can be genetically modified with synthetic receptors “CARs” that redirect their specificity against distinct tumor antigens. CAR T cells have proven more effective in B-cell malignancies than solid tumors, likely in part due to the metabolic milieu of solid tumors. At hypoxia, steep redox gradients suppress CAR T-cell function. NADH can be converted into NAD by the bacterial enzyme Lactobacillus brevis NADH Oxidase (LbNOX), which mimics the oxidative function of the electron transport chain without generating ATP. Here we test the ability of LbNOX to promote CAR-T cell metabolic activity and anti-tumor efficacy.
Tune in to learn more about:
- If lactate a friend or foe for CAR T-cells
- How hypoxia is detrimental to CAR T-cell metabolic function
- How to engineer CAR T-cell resilience against hypoxia